Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 26

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 26
---

nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect, and no proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification. The Company has no Subsidiaries required to be disclosed pursuant to Item 601(b)(21)(ii) of Regulation S-K, except as
set forth in the Company’s Annual Report on Form 20-F for its fiscal year ended December 31, 2023 filed with the SEC on April 19,
2024 (the “”).

| -12- |

(b) . (i) The Company has the requisite corporate power and authority to enter into and (subject to any applicable
rules and regulations of the Principal Market) perform its obligations under this Agreement, the Registration Rights Agreement and each
of the other Transaction Documents, and to issue the Securities in accordance with the terms hereof, (ii) the execution and delivery of
the Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby, including without
limitation, if applicable, the allotment of the Commitment Shares (as defined below in ) and the Purchase Shares issuable
under this Agreement, have been duly authorized by the Company’s Board of Directors (the “”)
and no further consent or authorization is required by the Company, its Board of Directors or its shareholders (except as provided in
this Agreement), (iii) each of this Agreement and the Registration Rights Agreement has been, and each other Transaction Document shall
be on the Commencement Date, duly executed and delivered by the Company and (iv) each of this Agreement and the Registration Rights Agreement
constitutes, and each other Transaction Document upon its execution on behalf of the Company, shall constitute, assuming the due authorization,
execution and delivery of the other party thereto, the valid and binding obligations of the Company enforceable against the Company in
accordance with their terms, except as such enforceability may be limited by (i) general principles of equity or applicable bankruptcy,
insolvency, reorganization, moratorium, liquidation or other laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies, (ii) laws relating to the availability of specific performance, injunct